Sylvia Cohen-Kaminsky

Director of Research at CNRS and Vice-Chair of the Scientific Council of the Paris Saclay Faculty of Medicine · CNRS, Inserm UMR S999, Universite Paris Saclay · company speakers →

Sylvia Cohen-Kaminsky is Director of Research at the French National Center for Scientific Research (CNRS) and Vice-Chair of the Scientific Council of the Paris Saclay Faculty of Medicine. She works in the Inserm UMR_S999 unit, which is dedicated to « Pulmonary Arterial Hypertension: Pathophysiology and Therapeutic Innovation » and directed by Pr Marc Humbert. She is co-founder and Head of Science of ALSYMO. This company promotes the results of her research after maturation at SATT Paris Saclay, the local technology transfer acceleration office. ALSYMO is developing an innovative therapeutic target and a first-in-class drug candidate protected by 3 families of patents issued worldwide for a disease-modifying treatment for Pulmonary Arterial Hypertension, a rare respiratory disease. This breakthrough innovation targets peripheral pulmonary vascular NMDA receptors, major players in vascular remodeling leading to PAH. The ambition is to bring this drug candidate to proof of human efficacy within 5 years. She holds a Ph.D. in Immunology, obtained in 1988, and a Habilitation to Direct Research (HDR), acquired in 1998. She is a 2020 graduate from the « Life Science Leadership School, » an original MBA-like program dedicated to life sciences and healthcare entrepreneurship. She began her career at CNRS in 1990, working on autoimmunity, before joining Inserm in 2010, where she coordinates multidisciplinary diagnostic and therapeutic innovation projects to improve PAH. Thanks to her experience in innovation, she is a member of the Inserm Scientific Committee of Specialists CSS3 « Physiology and pathophysiology of major systems », the Scientific and Strategic Steering Committee COSS Carnot AP-HP (Assitance Publique-Hopitaux de Paris), the National Research Agency (ANR) LabCom Committee (Joint Labs for research involving private-public collaborations), the ANR CE17 « Translational Research on Health » Committee, and was recently appointed an alternate member of the Board of Directors of SATT Paris Saclay. She is a member of international learned societies such as the ERS, the ATS, and the PVRI (Pulmonary Vascular Research Institute). As a member of the French Society for Immunology (SFI) since 1990 (board member 2006-2011 and general secretary 2012-2014), she has worked to promote equality for women in immunology and science. She represents the University Paris-Saclay on the Paris-Boston Women’s Forum, a network of universities for gender equality, an official initiative launched by the French Presidency of the G7. She is a Women in Sciences association member and participates in the Paris Saclay University Women in Sciences mentoring program dedicated to women PhD candidates.

Is this you? Claim this profile →